公开(公告)号：US20240342247A1

公开(公告)日：2024-10-17

申请号：US18577369

申请日：2022-07-08

Applicant: GILA THERAPEUTICS, INC.

Inventor： Thomas VASICEK

IPC: A61K38/22 ,  A61K38/23 ,  A61K38/26 ,  A61K38/28

CPC classification number: A61K38/22 ,  A61K38/2264 ,  A61K38/23 ,  A61K38/26 ,  A61K38/28

Abstract: The invention provides compositions and methods for inducing activating a neural receptor. The compositions include a metabolic hormone, which can be used to provide treatment for an addiction or mood disorder in a subject.

公开(公告)号：US12115341B2

公开(公告)日：2024-10-15

申请号：US14443847

申请日：2013-11-20

Applicant: AMGEN INC.

Inventor： Lawrence Ring ,  Dhairya Mehta ,  Stephanie Toy ,  Ferry Tamtoro ,  Alexander Stuart Cairns ,  Scott R. Gibson

IPC: A61M5/142 ,  A61K9/00 ,  A61K38/19 ,  A61K38/26 ,  A61K38/28 ,  A61M5/14 ,  A61M5/158 ,  A61M5/20 ,  A61M5/30 ,  A61M5/31 ,  A61M5/32 ,  A61M5/42 ,  A61M25/00 ,  A61M25/02 ,  C07K14/535 ,  C12N9/64

CPC classification number: A61M5/14248 ,  A61K9/0019 ,  A61K38/193 ,  A61K38/26 ,  A61K38/28 ,  A61M5/14 ,  A61M5/14216 ,  A61M5/158 ,  A61M5/20 ,  A61M5/3134 ,  A61M5/3286 ,  A61M5/3287 ,  A61M5/3291 ,  A61M5/422 ,  A61M25/0015 ,  A61M25/0068 ,  A61M25/007 ,  A61M25/02 ,  C07K14/535 ,  C12N9/6424 ,  A61M2005/1401 ,  A61M2005/1585 ,  A61M2005/3022 ,  A61M2005/3289 ,  A61M2025/0073 ,  A61M2202/0007 ,  A61K38/28 ,  A61K2300/00 ,  A61K38/26 ,  A61K2300/00 ,  A61K38/193 ,  A61K2300/00

Abstract: A drug delivery device includes a blunt cannula and a reservoir. The blunt cannula has a cylindrical wall that defines an axial passage between a first end and a second end of the blunt cannula. The wall has at least a first tapered region at the first end to define an opening in fluid communication with the axial passage and adapted at the first end to resist interruption of fluid flow through the axial passage and out of the first end of the blunt cannula. The reservoir is connected to the second end of the blunt cannula.

公开(公告)号：US20240335514A1

公开(公告)日：2024-10-10

申请号：US18746567

申请日：2024-06-18

Applicant: Boehringer Ingelheim International GmbH

Inventor： Rolf GREMPLER ,  Odd-Erik JOHANSEN ,  Thomas KLEIN ,  Gerd Roland LUIPPOLD ,  Michael MARK

IPC: A61K38/28 ,  A61K31/341 ,  A61K31/7048 ,  A61K45/06

CPC classification number: A61K38/28 ,  A61K31/341 ,  A61K31/7048 ,  A61K45/06

Abstract: The invention relates to a pharmaceutical composition according to the claim 1 comprising an SGLT2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions

公开(公告)号：US12104184B2

公开(公告)日：2024-10-01

申请号：US18068443

申请日：2022-12-19

Applicant: HALOZYME, INC.

Inventor： Ge Wei ,  H. Michael Shepard ,  Qiping Zhao ,  Robert James Connor

IPC: C12N9/26 ,  A61K9/00 ,  A61K38/00 ,  A61K38/28 ,  A61K38/47 ,  A61K45/06 ,  A61K47/10 ,  A61P35/00 ,  C07K14/47 ,  C12Q1/34

CPC classification number: C12N9/2474 ,  A61K9/0019 ,  A61K38/28 ,  A61K38/47 ,  A61K45/06 ,  A61K47/10 ,  A61P35/00 ,  C07K14/47 ,  C12Q1/34 ,  C12Y302/01035 ,  A61K38/00 ,  C07K2319/30 ,  G01N2333/926 ,  G01N2333/928 ,  Y02A50/30 ,  A61K38/28 ,  A61K2300/00 ,  A61K38/47 ,  A61K2300/00

Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

公开(公告)号：US20240301022A1

公开(公告)日：2024-09-12

申请号：US18598878

申请日：2024-03-07

Applicant: Aston University

Inventor： Michael J. Tisdale ,  Steven T. Russell

IPC: C07K14/47 ,  A23L33/17 ,  A61K9/00 ,  A61K31/137 ,  A61K31/138 ,  A61K38/17 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K47/60 ,  A61K47/61

CPC classification number: C07K14/473 ,  A23L33/17 ,  A61K9/0014 ,  A61K9/0043 ,  A61K9/0053 ,  A61K31/137 ,  A61K31/138 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1741 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  A61K47/60 ,  A61K47/61

Abstract: The invention provides formulations and methods for ameliorating symptoms associated with metabolic disorders, such as cachexia, hypoglycemia, obesity, diabetes, and the like by administering Zn-α2-glycoproteins or a functional fragment thereof, alone or in combination with additional agents, such as β adrenergin receptor agonists, β adrenergin receptor antagonists, and/or glycemic control agents.

公开(公告)号：US12064508B2

公开(公告)日：2024-08-20

申请号：US17836617

申请日：2022-06-09

Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD

Inventor： Elka Touitou ,  Hiba Natsheh

IPC: A61P25/16 ,  A61K9/00 ,  A61K9/107 ,  A61K31/047 ,  A61K31/05 ,  A61K31/135 ,  A61K31/165 ,  A61K31/192 ,  A61K31/4196 ,  A61K31/426 ,  A61K31/485 ,  A61K31/551 ,  A61K38/095 ,  A61K38/12 ,  A61K38/18 ,  A61K38/28 ,  A61K47/02 ,  A61K47/10 ,  A61K47/24

CPC classification number: A61K9/1075 ,  A61K9/0043 ,  A61K31/047 ,  A61K31/05 ,  A61K31/135 ,  A61K31/165 ,  A61K31/192 ,  A61K31/4196 ,  A61K31/426 ,  A61K31/485 ,  A61K31/551 ,  A61K38/095 ,  A61K38/12 ,  A61K38/1808 ,  A61K38/28 ,  A61K47/02 ,  A61K47/10 ,  A61K47/24 ,  A61P25/16

Abstract: The invention relates to a nasally administrable composition comprising at least one active substance in magnesium-containing vesicular carrier, said carrier comprising glycol, phospholipids, water and at least one magnesium source. Methods for nasal administration of the composition, for example, for pain relief, are also provided.

公开(公告)号：US20240261503A1

公开(公告)日：2024-08-08

申请号：US18638195

申请日：2024-04-17

Applicant: Insulet Corporation

Inventor： Bryan Mazlish ,  Lane Desborough

IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145 ,  A61K38/28 ,  A61M5/00 ,  A61M5/142 ,  A61M5/315 ,  G16H20/17

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61M5/14248 ,  G16H20/17 ,  A61B5/4839 ,  A61K38/28 ,  A61M5/003 ,  A61M5/31568 ,  A61M2205/35 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201

Abstract: A method of insulin delivery, the method may include obtaining one or more blood glucose readings of a user, and, based on the blood glucose readings, generating a set of insulin delivery actions that may include delivery of a baseline basal rate or predefined variations of the baseline basal rate. The method may also include monitoring previous insulin delivery actions to the user to determine whether the previous insulin delivery actions include insulin beyond a threshold amount, where the previous insulin delivery actions may include delivery of the baseline basal rate or predefined variations of the baseline basal rate, and, based on the previous insulin delivery actions including insulin beyond the threshold amount, adjusting the set of insulin delivery actions.

公开(公告)号：US20240252795A1

公开(公告)日：2024-08-01

申请号：US17295282

申请日：2019-11-19

Applicant: BIORA THERAPEUTICS, INC.

Inventor： Jeffrey A. Shimizu ,  Mitchell Lawrence Jones ,  Mark Sasha Drlik ,  Iman Niknia ,  Nathan John Muller ,  Tuyen Nguyen ,  Christopher Loren Wahl ,  Edward Mudge ,  Nicholas Mark Salt ,  Nia Eleri Stevens ,  Stuart Robert Abercrombie ,  Christopher Ian Bunce ,  Nelson Quintana

IPC: A61M31/00 ,  A61K38/17 ,  A61K38/26 ,  A61K38/28 ,  C07K16/24

CPC classification number: A61M31/002 ,  A61K38/1796 ,  A61K38/26 ,  A61K38/28 ,  C07K16/241 ,  A61M2210/106

Abstract: An ingestible device, includes a storage reservoir configured to store a dispensable substance and a pressurized chamber configured so that, when a restraining force is removed from the pressurized clamber, the dispensable substance exits the ingestible device via openings in the ingestible device.

公开(公告)号：US20240252659A1

公开(公告)日：2024-08-01

申请号：US18528165

申请日：2023-12-04

Applicant: Wayne State University

Inventor： Wei-Zen Wei ,  Richard F. Jones (Deceased) ,  Joyce Reyes ,  Heather Gibson

IPC: A61K47/58 ,  A61K31/337 ,  A61K35/76 ,  A61K38/28 ,  A61K39/00 ,  A61K39/39 ,  A61K47/54 ,  A61K47/69 ,  C07C227/16 ,  C07C229/22 ,  C07K16/28 ,  C08F120/36 ,  C08G81/02 ,  C12N15/86

CPC classification number: A61K47/58 ,  A61K31/337 ,  A61K35/76 ,  A61K38/28 ,  A61K39/001106 ,  A61K39/39 ,  A61K47/543 ,  A61K47/544 ,  A61K47/6909 ,  A61K47/6915 ,  A61K47/6921 ,  C07C227/16 ,  C07C229/22 ,  C08F120/36 ,  C08G81/027 ,  A61K39/001104 ,  A61K2039/585 ,  C07K16/2863 ,  C12N15/86

Abstract: Only limited success has been previously achieved from cancer vaccines targeting unmodified tumor-associated self-antigens and new compositions and methods are needed. Immunogenic compositions and methods of use thereof are provided according to the present disclosure which include a protein effective to stimulate immune activity against a tumor-associated self-antigen, or a variant thereof which is a tumor-associated self-antigen.

公开(公告)号：US20240245754A1

公开(公告)日：2024-07-25

申请号：US18289581

申请日：2022-05-31

Applicant: Zhong YIN

Inventor： Zhong YIN

IPC: A61K38/28 ,  A61K9/00 ,  A61K38/26 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61M37/00 ,  A61P3/10

CPC classification number: A61K38/28 ,  A61K9/0021 ,  A61K38/26 ,  A61K45/06 ,  A61K47/10 ,  A61K47/26 ,  A61K47/32 ,  A61M37/0015 ,  A61P3/10 ,  A61M2037/0023 ,  A61M2037/0053 ,  A61M2037/0061

Abstract: A composition of polyvinyl alcohol and a small molecule polyhydroxy compound is used as a substrate to prepare a microneedle having a strongly hydrophilic surface and a drug-loaded microneedle. The microneedle can be obtained by means of the compatibility of a polyhydroxy polymer polyvinyl alcohol and a small molecule polyhydroxy compound. The preparation of a blank microneedle and the drug loading are conducted in stages and the drug loading stage is not conducted at a high temperature. By means of the microneedle substrate composition, the blank microneedle prepared therefrom and the use of the blank microneedle in drug loading, the inherent surface strongly hydrophilic polarity of the polyvinyl alcohol is maintained, such that the drug-loading capacity and the in-vivo penetration capacity of the coated drug loading are significantly increased.